Iptacopan

Short Description:

API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status 
Iptacopan Hydrochloride 1646321-63-2  Feb, 2027   Jul.14, 2034  estimated PV Completion – Dec, 2026
Iptacopan Hydrochloride Monohydrate 2447007-60-3 Feb, 2027 May, 2041  estimated PV Completion – Dec, 2026

 

[Indication] 

1. Paroxysmal nocturnal hemoglobinuria (PNH):For the treatment of PNH in adult patients.

2. C3 glomerulopathy (C3G):For the treatment of C3G in adult patients to reduce proteinuria.

3. Immunoglobulin A nephropathy (IgAN):For the treatment of primary IgAN in adult patients with rapid progression risk to reduce proteinuria levels.


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us

    Products categories